Bausch + Lomb Phase 2 Trial for Post-Surgical Ocular Pain Candidate Fails Primary Endpoint
Bausch + Lomb (BLCO) reported that its phase 2 clinical trial for BL1332, a topical TRPV1 antagonist designed to treat post-surgical ocular pain, failed to meet its primary endpoint. The study did not demonstrate a statistically significant improvement in pain reduction compared to the vehicle at the 24-hour mark. The failure of this candidate represents a setback for the company's ophthalmic pipeline development. Investors will likely monitor how this affects Bausch + Lomb's long-term strategy regarding post-surgical pain management solutions.

Tickers: $BLCO
Topics: clinical trial failure drug development phase 2 results